Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Inbar Galia

2. Date of Event Requiring Statement (MM/DD/YYYY) 8/15/2021

3. Issuer Name and Ticker or Trading Symbol

TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
See "Remarks" /

(Street)

TEL AVIV, L3 6944020

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	4828	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units	⁽²⁾	⁽²⁾	Ordinary Shares ⁽¹⁾	22842	⁽³⁾	D
Restricted Share Units	⁽⁴⁾	⁽⁴⁾	Ordinary Shares ⁽¹⁾	14485	⁽³⁾	D
Stock Options (Right to Buy)	⁽⁵⁾	11/14/2021	Ordinary Shares ⁽¹⁾	3450	$19.16	I	By Spouse
Stock Options (Right to Buy)	⁽⁶⁾	11/14/2021	Ordinary Shares ⁽¹⁾	2255	$34.70	I	By Spouse

Explanation of Responses:
(1)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)	Restricted share units were granted on March 5, 2021, with 5,710 vesting on each of March 5, 2022, March 5, 2023 and March 5, 2024 and 5,712 vesting on March 5, 2025.
(3)	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
(4)	Restricted share units were granted on February 28, 2020, with 4,828 vesting on each of February 28, 2022 and February 28, 2023 and 4,829 vesting on February 28, 2024.
(5)	Stock Options were granted on March 3, 2018, with 1,150 vested on each of March 2, 2019, March 2, 2020 and March 2, 2021.
(6)	Stock Options were granted on March 3, 2017, with 563 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 566 vested on March 3, 2021.

Remarks:
EVP, Chief Human Resources Officer and Head of Global Communications, Brand and ESG

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Inbar Galia C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV, L3 6944020			See "Remarks"